Biotechnology company Cereno Scientific (Nasdaq First North: CRNO B) on Wednesday reported publication of the first peer-reviewed manuscript on its HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, disclosing molecular structure, mechanism of action and nonclinical pharmacology data supporting broad potential in cardiovascular and pulmonary diseases.

The publication demonstrates that CS014 delivers strong antithrombotic effects across small artery, large artery and large vein models at doses that preserve normal haemostasis and bleeding time. Data show maintained HDAC inhibitory activity, increased tissue plasminogen activator mRNA expression and substantially lower formation of the hepatotoxic 4-ene metabolite compared with valproic acid, supporting a differentiated safety profile.

Findings validate HDAC inhibition as a core mechanism underpinning CS014's potential to address interconnected processes of thrombosis, vascular remodelling and fibrosis. Results position CS014 as a next-generation HDAC inhibitor and novel chemical entity with potential application across thrombotic and fibrosis-driven cardiopulmonary conditions.

Cereno Scientific recently reported positive Phase I results confirming favourable safety and tolerability at and above exposure levels predicted to support maximal therapeutic effects based on nonclinical data. The company is preparing for Phase II development with an initial focus on idiopathic pulmonary fibrosis, targeting diseases with high unmet medical need.